Henrike Reder

Henrike Reder

Auto-generated profile, based on publicly available information

Henrike Reder

Department of Otorhinolaryngology, Head and Neck Surgery, University of Giessen, Giessen, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
HRHenrike Reder
Henrike Reder
VTVictor F. Taferner
Victor F. Taferner
CWClaus Wittekindt
Claus Wittekindt
ABAndreas Bräuninger
Andreas Bräuninger
ESErnst-Jan M. Speel
Ernst-Jan M. Speel
SWSteffen Wagner
Steffen Wagner

6 July 2020 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
SWSteffen Wagner
Steffen Wagner
EPElena-Sophie Prigge
Elena-Sophie Prigge
NWNora Würdemann
Nora Würdemann
HRHenrike Reder
Henrike Reder
ABAyman Bushnak
Ayman Bushnak
Jens Peter KlussmannJens Peter Klussmann
Jens Peter Klussmann
Background: A remarkably better prognosis is associated with oropharyngeal squamous cell carcinomas (OPSCC) driven by human papillomaviruses (HPV) compared with HPV-negative OPSCC. Consequently, de-escalation of standard treatment has been suggested. Due to modest specificity rates, debates are ongoing, whether p16INK4a, a surrogate marker for HPV-driven OPSCC, is sufficient to correctly identify those tumours and avoid substantial HPV misattribution and thus undertreatment of patients by de-escalation. Robust data estimating the proportion of potentially undertreated patients are missing. Methods: We assessed a large-scale cohort of consecutively included OPSCC diagnosed between 2000 and 2017 for HPV–DNA, HPV genotypes, p16INK4a expression and multiple tumour- and patient-related risk factors, and investigated their impact on patients’ survival in comprehensive uni- and multivariate analyses. Results: Aetiological relevance of HPV (p16INK4a- and high-risk HPV–DNA-positivity) was detected in 27.1% (n = 192) of OPSCC, with HPV16 being the most abundant HPV type (94.6%). In 5.5% patients (n = 39), p16INK4a overexpression but no HPV–DNA was detected. Principal component and survival analyses revealed that 60.6% of these p16INK4a-positive OPSCC lacking HPV–DNA did not resemble HPV16-driven but HPV-negative OPSCC regarding risk-factor profile and overall survival. Notably, this group represented 10.6% of all p16INK4a-overexpressing OPSCC. Conclusions: p16INK4a as a single marker appears insufficient to indicate OPSCC patients suitable for treatment de-escalation.

1 June 2019 in Oral Oncology
Verified
Journal Article
Closed access
HRHenrike Reder
Henrike Reder
SWSteffen Wagner
Steffen Wagner
UGUlrike Gamerdinger
Ulrike Gamerdinger
SSSarah Sandmann
Sarah Sandmann
NWNora Wuerdemann
Nora Wuerdemann
CWClaus Wittekindt
Claus Wittekindt

10 June 2021 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
SWSteffen Wagner
Steffen Wagner
EPElena-Sophie Prigge
Elena-Sophie Prigge
NWNora Würdemann
Nora Würdemann
HRHenrike Reder
Henrike Reder
ABAyman Bushnak
Ayman Bushnak
Jens Peter KlussmannJens Peter Klussmann
Jens Peter Klussmann